| ŽOURKOVÁ, Alexandra, Jan JUŘICA, Eva MCCASKEY HADAŠOVÁ a Lucie PULKRÁBKOVÁ. Fading of the inhibition of CYP2D6 after paroxetine treatment discontinuation. European Neuropsychopharmacology. Elsevier, roč. 18, suppl.4, s. S328-S329, 2 s. ISSN 0924-977X. 2008. |
Další formáty:
BibTeX
LaTeX
RIS
@article{777028,
author = {Žourková, Alexandra and Juřica, Jan and McCaskey Hadašová, Eva and Pulkrábková, Lucie},
article_number = {suppl.4},
keywords = {disinhibition; CYP2D6; paroxetine; poor metaboliser; phenotype; genotype},
language = {eng},
issn = {0924-977X},
journal = {European Neuropsychopharmacology},
title = {Fading of the inhibition of CYP2D6 after paroxetine treatment discontinuation},
volume = {18},
year = {2008}
}
TY - JOUR
ID - 777028
AU - Žourková, Alexandra - Juřica, Jan - McCaskey Hadašová, Eva - Pulkrábková, Lucie
PY - 2008
TI - Fading of the inhibition of CYP2D6 after paroxetine treatment discontinuation
JF - European Neuropsychopharmacology
VL - 18
IS - suppl.4
SP - S328-S329
EP - S328-S329
PB - Elsevier
SN - 0924977X
KW - disinhibition
KW - CYP2D6
KW - paroxetine
KW - poor metaboliser
KW - phenotype
KW - genotype
N2 - The study unswers an important question: how long persists the inhibition after paroxetine treatment? The inhibition of CYP2D6 could exclude any substrates of CYP2D6 from the therapy. 4 weeks period seem to be sufficient for restoration of metabolic activity of CYP2D6.
ER -
ŽOURKOVÁ, Alexandra, Jan JUŘICA, Eva MCCASKEY HADAŠOVÁ a Lucie PULKRÁBKOVÁ. Fading of the inhibition of CYP2D6 after paroxetine treatment discontinuation. \textit{European Neuropsychopharmacology}. Elsevier, roč.~18, suppl.4, s.~S328-S329, 2 s. ISSN~0924-977X. 2008.
|
